Trends and risk factors of antimicrobial resistance of Neisseria gonorrhoeae in Catalonia, Spain, 2022–2023
Year: 2026
Type: article
Study design: Observational Study
Abstract: Neisseria gonorrhoeae (NG) remains a major cause of sexually transmitted infections (STIs) in Europe. Increasing antimicrobial resistance (AMR) threatens treatments’ effectiveness and complicates control efforts. Continuous regional surveillance is essential to detect emerging trends and inform public health action. To describe NG epidemiology and AMR trends in Catalonia during 2022–2023, and identify associated resistance risk factors. Retrospective analysis of laboratory-confirmed NG cases reported to the Microbiological Reporting System of Catalonia and the STI Registry. Antimicrobial susceptibility testing (AST) was performed for seven antibiotics. Descriptive analysis and logistic regression were used to assess associations between AMR and demographic and clinical variables, including age, sex, sexual orientation and gender identity (SOGI) and anatomical site of infection. 23,968 NG cases were reported, representing an 18.9% increase in incidence from 2022 to 2023. Culture was performed in 5,158 cases, AST results were available for 4,709 isolates. Resistance was highest for ciprofloxacin (71.4%) and tetracycline (48.9%), followed by azithromycin (20.3%) and penicillin (10.2%). Cefixime and ceftriaxone resistance was negligible. Azithromycin resistance was independently associated with homosexual orientation (adjusted odds ratio (aOR): 2.08) and anal infection (aOR: 1.41). Age ≥ 25 years was associated with resistance to ciprofloxacin, tetracycline, and penicillin. High NG incidence and substantial resistance to older antibiotics, together with notable azithromycin resistance, underscore the need for sustained AMR surveillance, particularly among men who have sex with men (MSM) and in anal infections. Strengthening culture-based AMR surveillance, extragenital screening and targeted prevention strategies are essential to preserve effective treatment options.
Authors: Mercè Herrero, Sonia Broner, Naiana Pastrana-Batalla, Eduard Anfruns, Evelin López-Corbeto, Victoria González, Judit Serra-Pladevall, Nieves Larrosa, Jacobo Mendioroz, Pilar Ciruela, the Working Group of MRSC, Yuliya Poliakova, Mateu Espasa, Cristina Pitart, Berta Fidalgo, Isabel Pujol, Laura Solaz, Teresa Falgueras, Mayuli Armas, Ester Sanfeliu, Percy Juan Ayala, José Stavola, Carmen Mora, Frederic Gómez, Ester Picó, Araceli González, Claudia Miralles, José Carlos de la Fuente, Eduardo Padilla, Manuel Monsonís, Ferran Navarro, Alba Rivera, Elisenda Miró, Gloria Trujillo, Joan López, Antonio Casabella, Emma Padilla, Lorena Forqué, Sílvia Capilla, Montserrat Olsina, Pepa Pérez, Mar Olga Pérez, Francesc Xavier Queralt, Ester Clapés, Cristina Muñoz, Xavier Clivillé, Alba Bellés, Eric López, Inés Valle, Miriam Campos, Maria Navarro, Marc Garreta, Jesús Trejo, Belén Viñado, Ester del Barrio, Yannick Alan Hoyos, Jordi Cámara, David Sánchez, Rosa Costa, Maria Ángeles Dominguez, Jordi Niubó, Maria Dolores Quesada, Jun Hao Wang Wang, Aida Ramirez Marinero, Núria Torrellas, Rosalía Santos, Olga Gonzalez-Moreno, Albert Barragan, Ariadna Hernández, Elisabet Folch, Geraldine Quelis, Anna Llimós Fabregas, Natàlia Roca, Lourdes Montsant, Miquel Fantova Navarro, Marta Albaiges, Carles Alonso-Tarrés, Carla Benjumea, Manel Panisello, Marta Polo
Institutions: Agència de Salut Pública de Catalunya, Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública, Hospital Universitari de Vic, Centro de Investigación Biomédica en Red, Vall d'Hebron Hospital Universitari, Centro de Investigación Biomédica en Red Enfermedades Infecciosas
Language: English
Subfield: Microbiology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $2,890
OpenAlex ID: W7141695871
